Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100.

Smith, N F; Baker, S D; Gonzalez, F J; Harris, J W; Figg, W D; Sparreboom, A

Smith, N F; Baker, S D; Gonzalez, F J; Harris, J W; Figg, W D; Sparreboom, A.

Affiliation

Smith NF; Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892, USA.

Br J Cancer ; 98(10): 1630-2, 2008 May 20.

Article in En | MEDLINE | ID: mdl-18475295

Subject(s)

Antineoplastic Agents/pharmacokinetics; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors/pharmacology; Esters/pharmacology; Protein Kinase Inhibitors/pharmacokinetics; Quinazolines/pharmacokinetics; Spiro Compounds/pharmacology; Administration, Oral; Animals; Antineoplastic Agents/administration & dosage; Antineoplastic Agents/blood; Beverages; Biological Availability; Citrus paradisi; Erlotinib Hydrochloride; Female; Mice; Mice, Inbred BALB C; Mice, Transgenic; Protein Kinase Inhibitors/administration & dosage; Protein Kinase Inhibitors/blood; Quinazolines/administration & dosage; Quinazolines/blood; Random Allocation

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Spiro Compounds / Protein Kinase Inhibitors / Enzyme Inhibitors / Esters / Cytochrome P-450 CYP3A Inhibitors / Antineoplastic Agents Limits: Animals Language: En Journal: Br J Cancer Year: 2008 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google